Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 766-771

  Tsang, Owen T Y ^a   Zee, Jonpaul S T ^a   Chan, Jacky M C ^a   Li, Reggie S T ^a   Kan, Yee Man ^b   Li, Francis T W ^f   Lo, Fu Hang ^c   Chow, David A ^g   Cheung, Kent W L ^h   Chan, Kam Hon ⁱ   Yeung, Yat Wah ^d   Ng, Fook Hong ^j   Li, Michael K K ^e   Kwan, Wai Keung ^k   Lai, Thomas S T ^a  

^a PRINCESS MARGARET HOSPITAL   (Hong Kong)

^b KWONG WAH HOSPITAL   (Hong Kong)

^c UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^d Caritas Medical Centre Hong Kong   (Hong Kong)

^e TUEN MUN HOSPITAL   (Hong Kong)

^f PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^g TSEUNG KWAN O HOSPITAL   (Hong Kong)

^h QUEEN ELIZABETH HOSPITAL   (Hong Kong)

ⁱ NORTH DISTRICT HOSPITAL   (Hong Kong)

^j Ruttonjee and Tang Shiu Kin Hospitals   (Hong Kong)

^k YAN CHAI HOSPITAL   (Hong Kong)

more..

Author keywords

Chronic hepatitis C genotype 6; Pegylated interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GOUT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; THYROTOXICOSIS; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION;

EID: 77950135030     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06163.x     Document Type: Article

References (23)

1. World Health Organization. Hepatitis C. WHO fact sheet No 164. Cited 3 Jan 2002. Available from URL: http://www.who.int/inf-fs/en/fact164.html
2. Heintges T, Wands JR, Hepatitis C. Virus: epidemiology and transmission. Hepatology. 1997 26 : 521 526.
3. Chan GC, Lim W, Yeoh EK. Prevalence of Hepatitis C infection in Hong Kong. J. Gastroenterol. Hepatol. 1992 7 : 117 120.
4. Chau TN, Lai ST, Lai JY, Yuen H. Acute viral hepatitis in Hong Kong: a study of recent incidences. HKMJ 1997 3 : 261 266.
5. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community acquired hepatitis C in the United States. N. Engl. J. Med. 1992 327 : 1899 1905.
6. Prescott LE, Simmonds P, Lai CL et al. Detection and clinical features of hepatitis C virus type 6 infection in blood donors from Hong Kong. J. Med. Virol. 1996 50 : 168 175.
7. Zhou DX, Tang JW, Chu IM et al. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong. J. Med. Virol. 2006 78 : 574 581.
8. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C genotype 6: a comparison with genotype 1. J. Infect. Dis. 2003 187 : 1071 1074.
9. Yuen MF, Lai CL. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006 49 : 96 8.
10. Fung J, Lai CL, Hung I et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J. Infect. Dis. 2008 198 : 808 812.
11. Tsang OT, Zee JC, Chan JM, Li RS, Lai JY, Lai TS. A retrospective comparative study of pegylated interferon and ribavirin for the treatment of chronic hepatitis C genotype 6 and genotype 1 [Abstract]. Hepatology 2008 48 (Suppl 884A.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994 19 : 1513 1520.
13. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 1998 339 : 1485 1492.
14. Poynard T, Marcellin P, Lee SS et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 352 : 1426 1432.
15. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998 339 : 1493 1499.
16. Martinot-Peignoux M, Boyer N, Pouteau M et al. Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J. Hepatol. 1998 29 : 214 223.
17. Fang JW, Chow V, Lau JY. Virology of hepatitis C virus. Clin. Liver Dis. 1997 1 : 493 514.
18. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002 347 : 975 982.
19. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004 140 : 346 355.
20. Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am. J. Gastroenterol. 2008 103 : 1131 1135.
21. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
22. Jensen DM, Morgan TR, Marcellin P et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006 43 : 954 960.
23. Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin. Infect. Dis. 2008 46 : 78 84.